» Articles » PMID: 35406646

Effects of Sigma-1 Receptor Ligands on Peripheral Nerve Regeneration

Overview
Journal Cells
Publisher MDPI
Date 2022 Apr 12
PMID 35406646
Authors
Affiliations
Soon will be listed here.
Abstract

Peripheral nerve injuries lead to the loss of motor, sensory and autonomic functions in the territories supplied by the injured nerve. Currently, nerve injuries are managed by surgical repair procedures, and there are no effective drugs in the clinic for improving the capacity of axonal regeneration. Sigma-1 receptor (Sig-1R) is an endoplasmic reticulum chaperon protein involved in many functions, including neuroprotection and neuroplasticity. A few previous studies using Sig-1R ligands reported results that suggest this receptor as a putative target to enhance regeneration. The aim of this study was to evaluate the possible effects of Sig-1R ligands on axonal regeneration in a sciatic nerve section and repair model in mice. To this end, mice were treated either with the Sig-1R agonist PRE-084 or the antagonist BD1063, and a Sig-1R knock-out (KO) mice group was also studied. The electrophysiological and histological data showed that treatment with Sig-1R ligands, or the lack of this protein, did not markedly modify the process of axonal regeneration and target reinnervation after sciatic nerve injury. Nevertheless, the nociceptive tests provided results indicating a role of Sig-1R in sensory perception after nerve injury, and immunohistochemical labeling indicated a regulatory role in inflammatory cell infiltration in the injured nerve.

Citing Articles

Age and sex drive differential behavioral and neuroimmune phenotypes during postoperative pain.

Dos Santos N, Lenert M, Castillo Z, Mody P, Thompson L, Burton M Neurobiol Aging. 2022; 123:129-144.

PMID: 36577640 PMC: 9892227. DOI: 10.1016/j.neurobiolaging.2022.09.008.

References
1.
Mancuso R, Olivan S, Rando A, Casas C, Osta R, Navarro X . Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012; 9(4):814-26. PMC: 3480575. DOI: 10.1007/s13311-012-0140-y. View

2.
Bravo-Caparros I, Perazzoli G, Yeste S, Cikes D, Baeyens J, Cobos E . Sigma-1 Receptor Inhibition Reduces Neuropathic Pain Induced by Partial Sciatic Nerve Transection in Mice by Opioid-Dependent and -Independent Mechanisms. Front Pharmacol. 2019; 10:613. PMC: 6584826. DOI: 10.3389/fphar.2019.00613. View

3.
Zhu S, Wang C, Han Y, Song C, Hu X, Liu Y . Sigma-1 Receptor Antagonist BD1047 Reduces Mechanical Allodynia in a Rat Model of Bone Cancer Pain through the Inhibition of Spinal NR1 Phosphorylation and Microglia Activation. Mediators Inflamm. 2015; 2015:265056. PMC: 4677253. DOI: 10.1155/2015/265056. View

4.
Herrando-Grabulosa M, Gaja-Capdevila N, Vela J, Navarro X . Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis. Br J Pharmacol. 2020; 178(6):1336-1352. DOI: 10.1111/bph.15224. View

5.
Jia J, Cheng J, Wang C, Zhen X . Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Front Cell Neurosci. 2018; 12:314. PMC: 6158303. DOI: 10.3389/fncel.2018.00314. View